Abstract: Objective To determine activity and safety of capecitabine at a moderate dose of 2000 mg/(m²·d) for metastatic breast cancer. Methods In this retrospective trial,43 metastatic breast cancer patients received first-line capecitabine 2 000 mg/m² on days 1~14 every 3 weeks. Results 43 metastatic breast cancer patients received mean 8 cycles of capecitabine therapy.Median PFS was 7.1 months (95%CI:5.8~8.4).There were no difference among the first line,the second line and third line treatment 7.1 months,6.1 months,and 8.1 months respectively(P=0.390).Patients pretreated with both anthracycline and taxane therapy had a significantly shorter PFS(6.1months vs.7.1 months，P=0.038),but patients>65 years achieved a significantly longer PFS(8.1 months vs.6.1 months，P=0.045). Ninteen cases(44.2%) had hand-foot syndrome,a main toxicity. Conclusion Capecitabine at a moderate dose of 2 000 mg/（m²·d）is active and well-tolerated for metastatic breast cancer.